Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 122,600 shares, a growth of 63.7% from the February 13th total of 74,900 shares. Currently, 6.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 395,100 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on APTO shares. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, February 12th. Alliance Global Partners raised shares of Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. Finally, StockNews.com started coverage on shares of Aptose Biosciences in a research note on Wednesday, March 5th. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.00.

Aptose Biosciences Trading Down 2.4 %

APTO stock opened at $3.69 on Friday. Aptose Biosciences has a 12 month low of $2.39 and a 12 month high of $51.61. The company has a 50-day moving average price of $5.13 and a 200 day moving average price of $8.07. The stock has a market cap of $7.90 million, a PE ratio of -1.24 and a beta of 1.14.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.